Monitor for updates on the Type A meeting with the FDA and progress on resolving CMC issues. Watch for potential cash burn acceleration and need for additional financing to address manufacturing deficiencies.
Price Chart
Executive Summary
Grace Therapeutics updated its corporate presentation, disclosing that the FDA issued a Complete Response Letter (CRL) for its GTx-104 drug due to chemistry, manufacturing, and controls (CMC) issues, including leachable data and manufacturing compliance at its CDMO. The company plans to resolve these items and resubmit its NDA.
Key Facts
- FDA issued a Complete Response Letter (CRL) for GTx-104 due to CMC data package completeness and manufacturing readiness issues
- No clinical deficiencies were identified in the CRL
- Deficiencies include insufficient leachable data, need for tox risk assessment, and manufacturing compliance observations at the CDMO
- Company plans to request a Type A meeting with the FDA to clarify the path forward
- Phase 3 STRIVE-ON trial met primary endpoint with GTx-104 showing benefits vs oral nimodipine
- Company has $18.7M cash as of December 31, 2025
Financial Impact
Potential delay in GTx-104 approval timeline, requiring additional investment to resolve CMC issues
Risk Factors
- Regulatory delay in GTx-104 approval
- Potential need for additional financing to address CMC issues
- Risk of FDA reinspection before approval
- Competition from existing oral nimodipine treatments
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001140361-26-016834 |
| Document: ef20071554_8k.htm | 0001140361-26-016834 |
| Document: 0001140361-26-016834-index-headers.html | 0001140361-26-016834 |
| Document: 0001140361-26-016834-index.html | 0001140361-26-016834 |
| Document: 0001140361-26-016834.txt | 0001140361-26-016834 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 10, 2026 6w ago | Insider Cluster | $2.26 $2.22 | ▼ −1.77% | ▼ −2.62% | $1.93 (−14.60%) |
Aug 13, 2026 10w ago | 8-K | $2.07 $2.16 | ▲ +4.35% | ▲ +4.55% | $1.93 (−6.76%) |
Aug 13, 2026 10w ago | Press Release | $2.07 $2.16 | ▲ +4.35% | ▲ +4.55% | $1.93 (−6.76%) |
Aug 4, 2026 11w ago | Press Release | $2.14 $2.12 | ▼ −0.93% | ▼ −0.77% | $1.93 (−9.81%) |
Jul 28, 2026 12w ago | 8-K | $2.25 $2.08 | ▼ −7.56% | ▼ −6.02% | $1.93 (−14.22%) |
Jun 18, 2026 18w ago | 8-K | $2.38 $2.26 | ▼ −5.04% | ▼ −4.73% | $1.93 (−18.91%) |
Jun 18, 2026 18w ago | 8-K | $2.38 $2.26 | ▲ +5.04% | ▲ +4.73% | $1.93 (+18.91%) |
Jun 18, 2026 18w ago | Press Release | $2.38 $2.26 | ▲ +5.04% | ▲ +4.73% | $1.93 (+18.91%) |
Jun 5, 2026 20w ago | 8-K | $2.30 $2.33 | ▲ +1.30% | ▲ +1.60% | $1.93 (−16.09%) |
Apr 27, 2026 26w ago | 8-K | $2.16 $2.10 | ▲ +2.78% | ▲ +2.29% | $1.93 (+10.65%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers